To the full analysis
Glaukos stock: growth
GKOSGlaukos reported $507.44M in revenue for fiscal 2025, up 32.3% on the prior year, up 17.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
50.8%
per year from 2012 to 2025, per share 16.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 17.7% | 21.6% | 50.8% |
| Revenue per share | 11.9% | 8.0% | 16.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $2.43M | −$19.33M | −$20.99M |
| 2013 | $20.95M | −$12.64M | −$14.16M |
| 2014 | $45.59M | −$12.13M | −$7.98M |
| 2015 | $71.7M | −$37.24M | −$3.07M |
| 2016 | $114.4M | $4.52M | $6.03M |
| 2017 | $159.25M | −$92K | $19.2M |
| 2018 | $181.28M | −$12.95M | $8.55M |
| 2019 | $236.98M | $15.42M | −$5.09M |
| 2020 | $224.96M | −$120.35M | −$29.92M |
| 2021 | $294.01M | −$49.59M | −$23.08M |
| 2022 | $282.86M | −$99.2M | −$63.35M |
| 2023 | $314.71M | −$134.66M | −$78.01M |
| 2024 | $383.48M | −$146.37M | −$67.62M |
| 2025 | $507.44M | −$187.69M | −$54.01M |
Revenue by segment
How Glaukos Corporation makes its money and how that has shifted. Names are as the company reports them.
- Glaucoma$231.0M97%
- Corneal Health$6.0M3%
The company split earlier years differently. A history would not be comparable, so only 2019 is shown.
Figures as a table
| 2019 | Share 2019 | |
|---|---|---|
| Glaucoma | $230.97M | 97.5% |
| Corneal Health | $6.02M | 2.5% |
| Total revenue | $236.98M | 100% |
Revenue by region
Where Glaukos Corporation generates its revenue.
- United States74%
- Outside the US26%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $270.09M | $375.04M | 73.9% |
| Outside the US | $113.39M | $132.4M | 26.1% |
| Total revenue | $383.48M | $507.44M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.